Skip to content

Ketamine: all studies

Page 47 of 448: studies 461 to 470 of 4,475, newest first. Back to the ketamine overview

Research

Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.

European Child & Adolescent Psychiatry February 2026 Konstantinos N Fountoulakis, Paraskevi Tatsiopoulou, Athanasios Saitis et al.

Ketamine and esketamine have been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior in adults. The current paper aimed to systematically review the available data on their efficacy in children and adolescents. The MEDLINE was searched with the keyword 'esketamine' on July 5th, 2024 (by following the PRISMA statement)....

A systematic review of ketamine's anxiolytic potential in rodent behavioral models of anxiety and PTSD.

Pharmacology, Biochemistry, and Behavior February 2026 Alena Lemeshova, Kaya A Patel, Alexander J Bloom et al.

Ketamine, a nonselective NMDA-receptor antagonist, is an emerging therapeutic for treatment-resistant depression and could also be a promising treatment for anxiety and post-traumatic stress disorders. However, preclinical studies in these areas lack methodological standardization, limiting clinical translatability. This review evaluates ketamine's anxiolytic potential in rodents by examining...

The hippocampus as a central hub in ketamine's antidepressant action: from molecules to circuit rewiring.

Neuropsychopharmacology February 1, 2026 Dongsun Park, Gwangho Lee, Bokyum Kim et al. 1 citation

Ketamine has emerged as a rapid-acting antidepressant that challenges classical monoaminergic frameworks and highlights the importance of synaptic and circuit-level plasticity in mood regulation. This review examines the hippocampus as a key site through which ketamine exerts both rapid and sustained antidepressant effects. We synthesize evidence showing that ketamine enhances hippocampal...

ED95 of Ciprofol Combined with Esketamine or Sufentanil in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Dose-Finding and Randomized Controlled Trial

Drug Design, Development and Therapy February 1, 2026 Xiaoxue Qin, Hui Jiang, Yan Xie et al. 1 citation

Background: This study aimed to estimate the 95% effective dose (ED95) of ciprofol when combined with esketamine or sufentanil in elderly patients undergoing endoscopic submucosal dissection (ESD), and to explore the associated clinical and safety profiles of these sedation strategies. Methods: This study was conducted in two phases. In Phase 1, 44 patients aged 65– 80 years undergoing ESD were...

DOI: 10.2147/dddt.s595458 (opens in new tab) Ketamine Sufentanil Anesthesia Randomized controlled trial +7

A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program

Journal of Military, Veteran and Family Health February 1, 2026 Ian Stefanuk, Kaitlin Chivers-Wilson, Rakesh Jetly et al.

Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans, and the presence of multiple conditions requires innovative treatment approaches. The Newly Institute in Calgary, Alberta, Canada, has introduced a novel intervention combining sublingual ketamine therapy with a medically managed transdiagnostic...

DOI: 10.3138/jmvfh-2025-0009 (opens in new tab) Anxiety disorder Checklist Depression economics Intervention counseling +7

The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

Substance Use & Misuse February 1, 2026 Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.

Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...

Repeated 7-day exposure to ketamine induces anxiety-like behaviors and neuronal apoptosis in mice via DRD1-medicated inhibition of Akt/Gsk-3β phosphorylation.

Cell Biology and Toxicology January 30, 2026 Jia-Yi Wei, Peng Lv, Jiayu Zhang et al.

Repeated exposure to ketamine leads to mental behavioral disorders and cognitive deficits in mice. As a neurotransmitter receptor, dopamine receptor 1 (DRD1) is involved in mental regulation and memory formation. However, the role of DRD1 in ketamine's behavioral disorder and neurotoxicity remains unclear. We found that seven-day ketamine exposure induced anxiety-like, depressive-like behavior...

DOI: 10.1007/s10565-026-10149-4 (opens in new tab) Full text (opens in new tab) Anxiety-like behavior Apoptosis Drd1 Ketamine abuse

α-tocopherol alleviates ketamine toxicity in rat brain neurons.

BMC Pharmacology and Toxicology January 30, 2026 Enayatollah Seydi, Sana Ghanizadeh, Farzaneh Jokar et al.

Ketamine exhibits various pharmacological effects due to its high efficacy, but reports also indicate its potential to cause brain side effects and neurotoxicity. It can induce oxidative stress and impair mitochondrial function, although the exact mechanism of its neurotoxicity remains unclear. In this study, we examined the effects of α-tocopherol on ketamine-induced toxicity in rat brain...

Dissociating pain dimensions in cold allodynia: subanesthetic ketamine reveals heritable affective-motivational traits in mice.

Pain January 29, 2026 Nicole Richter, Stefanie Schmidt, Glauce Regina Pigatto et al.

Pain perception involves somatosensory-discriminative and affective-motivational components, mediated by separate brain circuits. Traditional mouse behavioral assays lack the resolution to disentangle this complexity. Recent studies using subanesthetic ketamine doses in the hot-plate test revealed a dissociation between paw lifts (somatosensory) and bites & licks (affective). In this study, we...

DOI: 10.1097/j.pain.0000000000003912 (opens in new tab) Full text (opens in new tab) Affective-motivational pain Cold allodynia Inbred mouse strains Ketamine metabolism +3

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi-modal neuroimaging.

Addiction January 29, 2026 Yi-Hsuan Liu, Chia-Chun Hung, Marc N Potenza et al.

Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working-memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear. In Taiwan, ketamine is predominantly consumed by smoking ketamine mixed...

DOI: 10.1111/add.70331 (opens in new tab) Full text (opens in new tab) Ketamine N‐methyl‐d‐aspartate receptors Functional neuroimaging Hippocampus +4